Tornier NV Upgraded to Outperform at BMO Capital Markets (TRNX)
Tornier NV (NASDAQ:TRNX) was upgraded by equities researchers at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a research report issued on Friday, TheFlyOnTheWall.com reports. The firm currently has a $24.00 price objective on the stock, up from their previous price objective of $20.00. BMO Capital Markets’ price objective would suggest a potential upside of 10.45% from the company’s current price.
Shares of Tornier NV (NASDAQ:TRNX) traded up 11.49% during mid-day trading on Friday, hitting $21.73. The stock had a trading volume of 541,015 shares. Tornier NV has a 1-year low of $15.17 and a 1-year high of $24.35. The stock has a 50-day moving average of $22.24 and a 200-day moving average of $20.52. The company’s market cap is $1.060 billion.
Tornier NV (NASDAQ:TRNX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter last year, the company posted ($0.28) earnings per share. Tornier NV’s revenue was up 11.2% compared to the same quarter last year. On average, analysts predict that Tornier NV will post $-0.54 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on TRNX. Analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Analysts at Barclays raised their price target on shares of Tornier NV from $23.00 to $26.00 in a research note on Thursday, June 5th. They now have an “overweight” rating on the stock. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $22.67.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.